The global antibody drug conjugates market size was valued at USD 13.63 billion in 2025 and is projected to grow from USD 15.13 billion in 2026 to USD 34.98 billion by 2034, registering a CAGR of 11.04% during the forecast period from 2026 to 2034. North America dominated the antibody drug conjugates market with a market share of 44.87% in 2025.
Download a Free Sample To learn more about this report,
Antibody drug conjugates are becoming highly valuable in the market, with currently 15 approved ADCs targeting 16 different indications for hematological and solid tumor malignancies as of June 2025. Pfizer Inc., AstraZeneca, Gilead Sciences, F. Hoffmann-La Roche Ltd., along with other pharmaceutical companies, are significantly investing in ADCs. Thus, market consolidation is a major driver boosting the revenue of global manufacturers.
The use of Enhertu through advancing payloads is a key trend in the U.S. market. For example, Enhertu with pertuzumab has delivered a 40.7-month progression-free survival compared to 26.9 months for standard chemotherapy. This showcases ADCs as a potential first line treatment of care in HER2+ metastatic breast cancer across North America.
This fuels the demand for Enhertu in North America, which, in turn, contributes to the market growth.
Global manufacturers are taking the ADC market towards consolidation by acquiring smaller companies to advance their clinical cancer pipelines. This highlights the importance of ADC innovation in the U.S.
The surge in ADC approvals has created supply challenges in the market. To overcome this, in January 2024, Samsung Biologics launched a new ADC facility, and Lonza also acquired Genentech's large-scale biologics manufacturing site in Vacaville in October 2024. These development shows that manufacturers are making production a strategic priority. Thus, manufacturers are scaling up production and securing supply chains to prepare for global demands and reduce the risk of shortage, thereby driving the market growth for ADCs.
Global manufacturers are focusing on replacing chemotherapy with ADCs is a major factor supporting the adoption of ADCs in cancer therapy.
Thus, by replacing chemotherapy, ADC manufacturers are developing new standards of care, where ADC is becoming a first-line treatment, which will boost the company’s revenue growth in the long run.
Pricing, reimbursement, and competitive pressure reduce the revenue per unit, even when the product volume rises are a major restraint for ADC manufacturers. Gilead’s public filings and quarterly reporting for 2024 call out reimbursement pressures, rebates, and competition as explicit risks that are lowering prices of branded ADCs.
Breast cancer is a major indication for ADC use; manufacturers are focusing on extending it into other solid tumors.
Thus, expanding into multiple cancers will help manufacturers to diversify revenue generation and gain a strong foothold in the market.
The Kadcyla segment dominated the market with a revenue share of 28.86% in 2025. This growth is attributed to its highest sales in the U.S. and the rest of the world. Additionally, in 2025, Roche expanded global access programs, showcasing Kadcyla in new healthcare systems across the Asia Pacific and Latin America, which led to increased market adoption. Moreover, the expanding application of Kadcyla for HER2-positive early breast cancer further drives the market penetration.
Request Customizationto receive a tailored report.
The breast cancer segment dominated the market in 2025 and is anticipated to register the fastest CAGR of 12.4% during 2026-2034. This dominance is attributed to the high prevalence of breast cancer worldwide and the increasing number of ADC approvals for breast cancer treatment. Currently, Kadcyla, Trodelvy, and Enhertu are highly revenue-generating ADCs that are primarily approved for the treatment of Breast cancer. Thus, all aforementioned factors support segmental market growth.
The HER2 segment dominated the market in 2025, as it is one of the best biomarkers in oncology treatment. Recently, Enhertu’s approval for HER2-positive targets has built physician trust, making HER2-targeted ADC a first choice in the treatment. Moreover, a high clinical trial success rate compared to other targets such as Trop-2 and CD30 has supported the positive clinical trial results of the HER2 target.
Speak to an Analystto discuss market opportunities.
North America dominated the antibody drug conjugates market in 2025, accounting for 44.87% market share. This dominance is attributed to strong clinical trial leadership, high uptake of ADCs, and a growing number of antibody approvals in the U.S. Furthermore, strong reimbursement support for high-cost oncology drugs is making ADCs available at low cost, leading to increased consumption. For instance, Trodelvy’s U.S. sales nearly doubled in 2024, showcasing high market uptake. Moreover, the region also benefits from a strong supply chain network, developed clinical infrastructure, and faster adoption of ADCs as compared to other regions.
Unlock Regional Insightsto access country-level data, & regional trends.
Asis Pacific is emerging as the fastest-growing region with a CAGR of 12.7% from 2026-2034, owing to increasing local innovations, strong regulatory support, and expanding patient access. In this region, countries such as China, Japan, and South Korea are developing their own ADCs. For example, in May 2025, RemeGen’s disitamab vedotin became the first China-approved ADC signaling domestic innovations. In addition, the growing cancer incidences and large patient population are also making the Asia Pacific the fastest-growing region. For example, in 2025, Daiichi Sankyo’s Datroway (datopotamab deruxtecan) was approved in Japan to treat the highly prevalent breast cancer.
U.S. accounts for the dominant share in the antibody drug conjugates market, driven by the highest number of ADC approvals, the development of novel ADCs through key market players, and a surge in patent application filing for ADCs. The table below highlights the number of ADC patents filed by various countries.
U.S. is the highest ADC patent-holding country, attributed to various factors such as high government investments (NIH Investment USD 47 Billion in 2024), which fuels the novel research that needs intellectual rights. Moreover, FDA’s leadership in approving ADCs like Trodelvy, Enhertu, and Padcev are making a big commercial market, giving manufacturers a strong motive to secure their drug with a patent.
China antibody drug conjugates market growth is driven by a surge in ADC clinical trials, increasing prevalence of cancers and autoimmune diseases, and accelerated development of domestic ADCs. Furthermore, China is also becoming the largest filer of patents across the globe through companies such as RemeGen, taking the lead with its ADC disitamab vedotin, being among the first approved in China. Moreover, the Chinese government has also prioritized biotech in its national policies, making funding and approvals faster for ADCs.
Germany's market is witnessing significant growth due to strong demand for targeted therapies and rising cancer incidences. Additionally, innovation in linker technologies for non-cleavable linkers, as in Kadcyla, further supports the market growth. Moreover, local manufacturing hubs are expanding ACD pipelines by raising funding for ADC research, thus creating new opportunities for market growth.
Switzerland’s advancement is driven by Roche’s ADCs, such as Kadcyla, and Lonza, known as one of the largest ADC manufacturing hubs in the country. These factors are collectively driving the ADC market growth in Switzerland. Moreover, growing R&D investment by domestic players to support ADC pipelines and a favorable European regulatory framework drive the market growth for antibody drug conjugates.
Japan is an emerging country in the antibody drug conjugates market, due to strong regulatory support leading to new ADC approvals. For instance, Japanese company Daiichi Sankyo significantly contributes to ADC innovations and currently has 3 candidates in the clinical pipeline. The company is also partnered with AstraZeneca for Enhertu. All the aforementioned factors position Japan as an emerging player in the market.
The global antibody drug conjugates market is highly consolidated, with fewer players accounting for the maximum market share. The major key players in the market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, AbbVie Inc., Gilead Sciences, and others.
These players are actively engaged in various market strategies such as product approval, partnership, acquisition, and product launch to remain competitive in the market.
RemGen is a domestic manufacturer and developer of ADCs in China. The company is actively engaged in novel ADC development through partnerships with global companies. The company is emerging as a significant player in the market through its recent ADC approval.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Lidocaine Market Size, Share, Growth, Analysis, Report, 2034
Scar Treatment Market Size, Share, Growth, Analysis, Report, 2034
Ophthalmic Drugs Market Size, Share, Growth, Forecast, 2034
Precision Medicine Market Size, Share, Growth, Analysis, 2034
Opioids Market Size, Share, Growth, Analysis, Report, 2034
Bioidentical Hormones Market Size, Share, Report, 2034
We are featured on:
sales@straitsresearch.com